Complications of portal hypertension, including ascites, gastrointestinal bleeding, hepatic
hydrothorax, and hepatic encephalopathy, are associated with significant morbidity and …

Budd-Chiari syndrome and non-cirrhotic non-tumoral portal vein thrombosis are 2 rare
disorders, with several similarities that are categorized under the term splanchnic vein …

These guidelines on transjugular intrahepatic portosystemic stent-shunt (TIPSS) in the
management of portal hypertension have been commissioned by the Clinical Services and …

Budd Chiari syndrome (BCS) is a diverse disease with regard to the site of obstruction, the
predisposing thrombophilic disorders and clinical presentation across the Asia-Pacific …

The Billroth III guidelines were developed during a consensus meeting of the Austrian
Society of Gastroenterology and Hepatology (ÖGGH) and the Austrian Society of …

BACKGROUND & AIMS: Data on the management of portal vein thrombosis (PVT) in
patients with decompensated cirrhosis are extremely limited, particularly in the cases of the …

Abstract Background Budd–Chiari syndrome (BCS) is a rare disease characterized by
hepatic venous outflow tract obstruction (HVOTO). Methods Recent literature has been …

Background Budd-Chiari syndrome (BCS) is an eponym that includes a group of conditions
characterized by partial or complete hepatic venous tract outflow obstruction, and the site of …

Background China may have the largest number of Budd–Chiari syndrome (BCS) cases in
the world (at least 1914 original papers were published, and at least 20 191 BCS patients …

Background and Aims Direct oral anticoagulants (DOACs) may simplify management of
Budd-Chiari syndrome (BCS). Here, we report our experience with off-label use of DOACs …